title: Antioxidant agents and physiological responses in adult epileptic patients treated with lamotrigine.
abstract: BACKGROUND
  The aim of our research was to evaluate some biochemical changes in blood during lamotrigine (LTG) monotherapy of adult patients with epilepsy, and to check possible associations between typical selenium status parameters and the frequency of seizures.
  
  
  METHODS
  The study was performed by examining aspartate aminotransferase (AspAT), alanine aminotransferase (AlaAT), creatinine, ferric reducing ability of plasma (FRAP), serum uric acid (UA), uric-acid-independent FRAP (UAiFRAP), plasma glutathione peroxidase (GPX3), selenoprotein P (SelP), plasma superoxide dismutase (pSOD), 8-hydroxy-2'-deoxyguanosine (8-OHdG) in serum and urine, serum selenium (sSe) and zinc (sZn), in 22 adult patients with epilepsy and 22 healthy controls. Additionally, the levels of LTG were determined in patients.
  
  
  RESULTS
  pSOD activity was higher in the study group (5.32±1.24 U/ml) compared with the controls (4.05±0.92 U/ml, p=0.008). No other statistical difference between patients and controls was found.
  
  
  CONCLUSIONS
  Lack of difference in parameters other than SOD, particularly no difference in 8-OHdG concentrations between the patients treated with LTG compared to the control subjects suggests that these patients are at no particular risk of oxidative DNA damage. In patients who are well or moderately well clinically controlled, selenium status parameters (sSe, GPX3, SelP) are not directly connected with the frequency of seizures.
authors.affiliation: Antiepileptic Outpatient Clinic, Provincial Hospital No. 2, Lwowska 60, PL 35-301 Rzeszów, Poland. elapp13@wp.p
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Płonka-Półtorak
authors.forename: Paweł
authors.initials: P
authors.lastname: Zagrodzki
authors.forename: Fergus
authors.initials: F
authors.lastname: Nicol
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Kryczyk
authors.forename: Henryk
authors.initials: H
authors.lastname: Bartoń
authors.forename: Tuomas
authors.initials: T
authors.lastname: Westermarck
authors.forename: Pekka
authors.initials: P
authors.lastname: Kaipainen
authors.forename: Sakaewan
authors.initials: S
authors.lastname: Ounjaijean
authors.forename: Markus
authors.initials: M
authors.lastname: Kaski
authors.forename: Faik
authors.initials: F
authors.lastname: Atroshi
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism*; D016022:Case-Control Studies; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D012643:Selenium / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D014227:Triazines / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D000975:Antioxidants; D014227:Triazines; D000080242:8-Hydroxy-2'-Deoxyguanosine; D013482:Superoxide Dismutase; D003849:Deoxyguanosine; D012643:Selenium; D000077213:Lamotrigine